Navigation Links
BioMarin to Present at the Deutsche Bank Health Care Conference
Date:5/12/2009

NOVATO, Calif., May 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Deutsche Bank 34th Annual Health Care Conference in Boston on Tuesday, May 19, 2009 at 1:55 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Corporation, an innovator of advanced optical instruments, announced ... with Harvard University granting Nikon the rights to ... Under the terms of the agreement, Nikon will ... with the N-STORM name. ,, Nikon Corporation ...
(Date:12/3/2009)... Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ... for the second quarter of fiscal year 2010 on December ... conference call and webcast to discuss the results at 11:30 ... will discuss financial results for the second quarter ended October ...
(Date:12/2/2009)... Biosciences Corporation (Nasdaq: MATK ) announced today that it ... fiscal year 2009 on December 16, 2009, at approximately 4:00 ... p.m. ET Martek will conduct a conference call to discuss ... to the call live via webcast by visiting Martek,s web ...
(Date:12/2/2009)... announces that a new market research report ... Drug Discovery Technologies - A Global Update ... http://www.reportlinker.com/p0164246/Drug-Discovery-Technologies---A-Global-Update-of-Market-Trends--Opportunities.html ,, Drug discovery has ... every pharmaceutical company,s business strategy. There are ...
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
... BOTHELL, WA, and VANCOUVER, April 9 /PRNewswire-FirstCall/ - OncoGenex ... OGXI ), announced today that it has been named ... LifeSciences British Columbia. This annual award is presented by ... has made outstanding contributions to the development of British ...
... a provider of nanoproteomic analysis systems to life science ... Series C financing led by its largest shareholder, the ... Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada ... are very happy to announce this financing in the ...
... April 9 Cepheid (Nasdaq: CPHD ) ... fiscal first quarter ended March 31, 2009, on Thursday, April ... host a management presentation at 2 p.m. Pacific Time on ... access the live webcast, please visit Cepheid,s website at ...
Other Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:12/4/2009)... is challenging accepted thinking about amyloids the fibrous protein ... and may open up a potential new area for therapeutics. ... made up of proteins sometimes known as fibres - are ... formation which can damage cells and cause disease. , ...
(Date:12/3/2009)... and animal species can be likened to emptying a museum ... medicines into the trash, or replacing every local cuisine with ... habitats may not just make the world boring. New research ... for catching some nasty disease. , "Habitat destruction and biodiversity ...
(Date:12/3/2009)... N.M. Most scientists believe that staph infections are caused ... toxins. The signaling process is called quorum sensing because many ... the Jeff Brinker research group has determined that the very ... harmless to a virulent form, occurs in a single cell ...
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Mad genius 3A Study suggests link between psychosis and creativity 10132 1Mad genius 3A Study suggests link between psychosis and creativity 10132 2Improved Screening for Jaundice Can Protect Newborns 58406 1Improved Screening for Jaundice Can Protect Newborns 58406 2New study resolves the mysterious origin of Merkel cells 58402 1
... central nervous system that occurs primarily in the brain has ... the University of California, San Francisco. , Known ... Findings from a group of 12 study patients showed that ... the patient’s immune system to attack the tumor cells, a ...
... Africa were cracking nuts with stone tools before the ... suggests chimpanzees developed this behaviour on their own, or ... from our common ancestor. Julio Mercader, Christophe Boesch and ... Cote d'Ivoire, the only known prehistoric chimpanzee settlement. ...
... scientists in collaboration have developed a new technique for ... based on a GFP-aequorin fusion protein. This imaging technique ... calcium activity), real-time and in-vivo, in either a small ... whole. , Participating in the development were The ...
Other Biology News:UCSF brain tumor vaccine trial shows promising results 2UCSF brain tumor vaccine trial shows promising results 3The chimpanzee stone age 2Bioluminescence at the service of a novel cerebral imaging technique 2Bioluminescence at the service of a novel cerebral imaging technique 3
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The external laser upgrade for the Molecular Imager FX adds a 635 nm external laser; the 555 nm long pass filter is replaced with a 605 nm band pass filter to distinguish Cy5 from 532 nm excitable dy...
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
Biology Products: